Drugs / HS-10390
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05942625 | May 2023 → Jun 2024 overdue | IgA glomerulonephritis, focal segmental glomerulosclerosis | Hansoh BioMedical R&D Company | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07555054 | May 2026 → Nov 2027 expected | chronic kidney disease | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06635772 | Nov 2024 → Dec 2025 overdue | IgA glomerulonephritis | Hansoh BioMedical R&D Company | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS-10390 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06635772 ↗ |
| Route | Oral | “Oral administration of specified dose of HS-10390” NCT05942625 ↗ |